LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach

31/01/2023
PRESS RELEASE

Brussels, 31 January 2023 - Today, EuropaBio publishes the report and recommendations on unmet medical needs (UMN) from its 1 December 2022 invite-only event. In response to the growing public debate about UMN, EuropaBio hosted multiple stakeholder groups to discuss and better understand patients’ with UMN experiences and facilitate progress towards a common understanding of the concept.

“The Patient BioForum is an important forum for multi-stakeholder discussions between industry and patient groups. Our discussions confirmed that a rigid approach to UMN risks having unintended consequences for patients and innovation. To address the challenges of UMN, the EU needs to create a multi-stakeholder forum to help dialogue and collaboration between policy-makers and stakeholders, with patient voices strongly represented”, said Claire Skentelbery, Director General of EuropaBio.

The report issues the following recommendations to the European Commission, the European Parliament, and the Council of the European Union to enable Europe to address the challenge of UMN:

➢ A multi-stakeholder approach is necessary where patient representatives are involved on an equal footing as other stakeholders and their voices duly considered
➢ Non-legislative approaches to UMN should be privileged to ensure Europe’s approach is scientifically sound, flexible, and future-proof to accommodate the rapid evolution of treatments, science, and disease understanding
➢ A life-cycle approach, from the translation of basic science to innovative therapies as well as care provision and patients is necessary to accommodate for current and future UMN
➢ Significant investments in science and society, by supporting Europe’s life science sector from scientific research to clinical development by positively rewarding innovation and maximising synergies between public and private actors, are necessary to ensure life-changing treatments reach the most patients.

Today, EuropaBio also launches its call for the creation of a multi-stakeholder forum to support reaching a common understanding of UMN and, most importantly, how it may support scientific progress, translational research, and therapeutic development that will improve the lives of millions of patients.

Several organisations, including DIG PKU and ESPKU, have already expressed their support to the initiative and EuropaBio intends to continue to engage with relevant stakeholders.

“Addressing unmet medical needs represent an important challenge for Europe that will require positive tools to stimulate innovation and deliver for patients and society. Addressing unmet medical needs will require us to break the silos and work together toward a common goal, making sure patients’ voices and experiences are heard. We need to adopt a balanced and careful approach and ensure no patients’ needs are unmet”, said MEP Pernille Weiss (EPP, Denmark).

EuropaBio Patient BioForum Report: Toward a Common Understanding of Unmet Medical Needs


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.